Prima BioMed Unveils Phase I Combination Study of IMP321 +

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor

SYDNEY, AUSTRALIA--(Marketwired - Nov 18, 2015) - Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD )

Highlights

  • Prima to run a Phase I safety and dose finding study of IMP321 in combination with a checkpoint inhibitor in metastatic melanoma in Australia
  • Potentially revolutionary study in immuno-oncology by combining APC activator with checkpoint inhibitor
  • The Human Research Ethics Committee at the Greenslopes Private Hospital in Queensland has cleared the study protocol
  • First patient expected to enter study in early 2016

Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD ) today unveiled a new clinical trial of IMP321, to be called 'TACTI-mel', short for ' T wo ACT ive I mmunotherapeutics in mel anoma'. In this ground-breaking safety and dose finding study IMP321 will be combined with an approved checkpoint inhibitor in patients with metastatic melanoma.

The Human Research Ethics Committee at the Greenslopes Private Hospital in Greenslopes, Queensland has approved Prima's Phase I clinical trial protocol, and it is expected that the first patient in the TACTI-mel study will be dosed in the first half of 2016. This will represent one of the first clinical occasions in which an Antigen Presenting Cell (APC) activator has been combined with a checkpoint inhibitor.

Prima CSO and CMO, Dr. Frederic Triebel commented: "The TACTI-mel study represents a significant development for Prima BioMed because the future of immuno-oncology lies in combination therapies. If we can combine IMP321 synergistically with a checkpoint inhibitor, as the pre-clinical evidence has suggested, then we will be well positioned in this revolutionary field."

The importance of the TACTI-mel study for Prima lies in the role that checkpoint inhibitors have started to play in the treatment of cancer. The checkpoint inhibitors are monoclonal antibody drugs which target certain inhibitory 'checkpoints' on immune cells. The regular function of such checkpoints is to supress an immune response and cancer is able to exploit the checkpoints to prevent the immune system from attacking tumours.

The checkpoint inhibitors, by foiling this tumour escape route, allow a more effective immune response, leading to significant beneficial outcomes for many patients. Three checkpoint inhibitors have gained FDA approval since 2011, all initially in metastatic melanoma. As previously outlined in its materials, Prima believes that the checkpoint inhibitors represent a cancer treatment revolution 1 , and that showing IMP321 to be synergistic with the checkpoint inhibitors will increase its clinical and commercial potential. The pre-clinical and clinical evidence to date has suggested that IMP321 can treat cancer by activating APCs to sustain an anti-cancer immune response. This is a markedly different mechanism of action from the checkpoint inhibitors, and suggests that the two approaches can be used synergistically in combination. Prima advised the market in May 2015 that it had filed a provisional patent application over the use of IMP321 in combination with immune checkpoint inhibitors, thereby potentially providing patent exclusivity for the product to 2035 or beyond if granted. TACTI-mel now builds on the work that went into that patent filing by taking the concept into the clinic to evaluate its safety as well as the ideal dosing combination.

TACTI-mel will be the second clinical study to be initiated for IMP321 since Prima BioMed acquired the compound in December 2014.

Clinical trial summary

TACTI-mel will recruit 24 patients with Stage III/IV metastatic melanoma being treated with an approved checkpoint inhibitor and add IMP321 to the dosing regimen. Patients will receive ascending subcutaneous doses of IMP321 up to 30 mg per injection fortnightly for 13 injections. The study will mainly evaluate the safety, pharmacokinetics, pharmacodynamics and anti-tumour activity of IMP321 at the various doses as well as the nature of the immune response in the combination. The primary endpoint of the study will be safety.

About IMP321

IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. IMP321 has been shown in an open-label Phase I study to be able to double the expected six-month response rate in HER-2 negative metastatic breast cancer patients receiving standard-of-care paclitaxel, from a 25% historic response rate (RECIST criteria) 2 to 50% when combined with IMP321 3 .

About Prima BioMed

Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses for cancer chemo-immunotherapy and in other combinations which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au

1 See the Prima BioMed Detailed Backgrounder presentation of 27 February 2015. 2 Miller et. al., N. Engl. J. Med. 2007, 357: 2666-76. 3 Brignone et.al., J. Transl. Med. 2010, 8:71.

For further information please contact: Prima BioMed Ltd: Stuart Roberts +61 (0) 447 247 909 stuart.roberts@primabiomed.com.au U.S. Investors: Matthew Beck The Trout Group LLC +1 (646) 378-2933 mbeck@troutgroup.com Australia Investor/Media: Mr Matthew Gregorowski Citadel Communications +61 (0) 422 534 755 mgregorowski@citadelpr.com.au

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 102

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 80

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 112

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 22

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 64

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 11

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 71

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies

Updated Category News Views 313

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies VICTOR Super Premium Pet Food, known for its dedication to high-quality pet nutrition, is proud to unveil a new line aimed specifically at canines with sensitive skin and stomach issues. The Sensitive Skin and Stomach line is designed to meet the dietary needs of both adult dogs and puppies, and will be...

Continue Reading
Exploring the Growth of the Pressure Monitoring Market

Updated Category News Views 181

The Expanding Pressure Monitoring Market This flourishing sector is gaining significant traction, reflecting a market valued at approximately US$13.63 billion in 2024, with a current rise to US$14.56 billion in 2025. The forecast indicates a notable compound annual growth rate (CAGR) of 8.3% from this point through 2032, culminating in an anticipated valuation of US$25.48...

Continue Reading
Citadel Credit Union Champions Community Engagement Initiatives

Updated Category News Views 636

Citadel Credit Union's Commitment to Community Support Citadel Credit Union is dedicated to reaffirming its commitment to its members and the surrounding region through an innovative approach to philanthropy. The organization has escalated its focus on community partnerships and employee-driven initiatives, making strides toward becoming a leader in promoting meaningful...

Continue Reading
TRIMEDX Bolsters Leadership with New Chief Data & AI Officer

Updated Category News Views 163

TRIMEDX Elevates Leadership with a Visionary Hire Indianapolis—TRIMEDX, a leading name in independent clinical asset management, is taking substantial strides in enhancing its technological offerings. The company has recently welcomed Srilekha Akula as its Chief Data & AI Officer. Her arrival marks a pivotal moment in TRIMEDX's journey, aimed at fostering innovation and...

Continue Reading
Exploring the Leadership of Ford as a Dividend Powerhouse

Updated Category News Views 170

Ford Motor Company (NYSE: F) has been a staple name in the automotive sector, but it’s got some serious hurdles to jump over. The stock price took a 12% nosedive over the past year, and while that might raise eyebrows, it also sets the stage for potential dividend plays. The price-to-earnings ratio is sitting pretty low at 11—sounds tempting for those looking at...

Continue Reading